Precisio Biotix is creating precision biologial antibacterials with an emphasis on topical diseases. Subsidiary companies are:
(1) Lysigen, which develops first or best-in-class lysins; and (2)
Precisiobiotix Technologies, which develops sustained release topical phage solutions.
Treating multiple bacterial conditions utilizing first or best-in-class lysins with an emphasis on lung and topical treatments.
>More
Preventing and treating AMR resistant topical infections utilizing novel sustained release phage spray and patch systems.
Lead product is for the prevention of topical AMR infections. See further
>More
Antibiotic Resistance - The Need for New Treatments
According to WHO, if we do not take significant action, we will enter a post-antibiotic era in which a common infection and minor injury can be life-threatening. It is estimated that by 2050 more people will die from infection than from cancer.
>More
Contact Us
Precisio Biotix Therapeutics
Tel: 86-21-61500300
Email: shencj@precisiobiotix.com
